Twist Oncology – DNA CGP Panel

/in /by

PRODUCTS

Comprehensive Genomic Profiling for Oncology Research

Get a Quote
The new Twist Oncology - DNA CGP panel offers 562-gene coverage for complete tumour profiling

Comprehensive Genomic Profiling (CGP) uses next-generation sequencing (NGS) to evaluate multiple clinically relevant biomarkers within a solid tumor. It provides detailed genomic resolution, enabling the detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), select gene fusions, and key cancer genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI).

By consolidating this information into a single assay, CGP offers a complete view of a tumor’s molecular profile, reducing the need for multiple tumor-specific panels or separate testing methods.

Why CGP Matters

Unified Testing Platform

Combines samples from all tumor types into a single test platform, enabling efficient batching and streamlined workflow.

Actionable Insights

Focuses on clinically and research-relevant information, supporting treatment decisions and drug development strategies.

Cost-Effective Efficiency

More efficient and economical than whole-exome sequencing (WES) for oncology, lowering resource use while maintaining comprehensive genomic coverage.

Chris Wicky

Clinical Genomics Manager - ANZ & Country Manager - NZ

If you’d like to see how this fits your current setup, I can walk you through integration options or pilot testing. The new Twist Oncology – DNA CGP Panel provides 562-gene coverage for comprehensive tumor profiling.
Get In Touch Today
Twist Tumor DNA CGP Panel

Enable improved Tx Selection and enhanced Clinical Research 

Fixed Panel + Customisation Options

FIXED PANEL

  • 562 genes analyzed for SNVs and hotspot mutations (+39 genes compared to TSO500)

  • Microsatellite instability (MSI) detection across ~50 sites

  • Copy number variation (CNV) analysis for 57 clinically relevant genes

  • Selected fusions and tumor mutational burden (TMB) scoring for complete tumor profiling

CUSTOMISATION OPTION

  • Add custom biomarkers to differentiate your lab’s testing capabilities

  • Adaptable for specific clinical or research needs

End-to-End Twist NGS Workflow Compatibility:

  • Library preparations: EF2.0, cfDNA

  • Hybridization solutions with options for software analytics

  • Streamlined workflow for enhanced lab efficiency

Now available in Australia and New Zealand through Decode Science.

Example Data Metrics

Example sequencing QC metrics averaged across data down sampled to 2000x raw coverage (32M 2×150 reads). 4.5 Gb of Data is enough for VAF detections ranging ~2%. Data available upon request.

Panel target size2.4 Mb
Example input 50 ng
Mean Target Coverage515x
On-Target Rate77%
Fold-80 Base Penalty1.32
Duplication Rate20%
Target bases covered >100x 99.5%
Advantages of Twist Oncology Panel
CONTENT

TSO-500 : Content is locked at 523 genes in 2025 and beyond

Twist CGP : Offers an updated CPG panel of 562 genes with Twist dsDNA probes

CUSTOMISATION

TSO-500 : Not Possible

Twist CGP : Can easily modify content to add genomic features or new biomarkers

COMPATIBILITY

TSO-500 : Product is locked into Illumina Platform Ecosystem

Twist CGP : Twist can enable Illumina short-read platforms and non-Illumina platforms (Ultima, Element, etc.)

WORKFLOW

TSO-500 : Requires an overnight capture + 2nd Hybridization Capture

Twist CGP : Single overnight hybridization capture (Option Trinity on Element)

COMPETITIVE PRICING

TSO-500 : High cost per sample for IVD kit pricing

Twist CGP : Can offer competitive pricing and modular kit options.

MODULAR PRODUCT

TSO-500 : Purchase is an all inclusive kit, no option for purchasing components

Twist CGP : Twist can sell modules, or custom configurations through OEM services

Customer Testimonial
"At LifeStrands Genomics Australia, we rely heavily on Twist’s NGS probes and reagents across nearly all our assays... Twist’s probe design flexibility and scalability have allowed us to tailor both DNA and RNA panels that suit a wide range of solid tumours without compromising sensitivity or turnaround times. We view Twist not just as a vendor, but as a strategic partner in advancing precision oncology."
Dr. Vivek Rathi, MD MSc FRCPA
Medical Director LifeStrands Genomics Australia (Genoox User)
Ready To Order?
As the official distributor for Twist Bioscience in Australia and New Zealand, Decode Science makes accessing CGP Panel straightforward. Our role is to connect your lab with Twist’s advanced technologies, ensuring you get the right custom panel solution for your sequencing projects—delivered locally with support when you need it.
Get a Quote